a public good project by the
Synthesis
Company
of California

© 2026

Juan W. Valle | doi.page

0 works0 citations0 h-index

Juan W. Valle

Cancer Research UK Manchester Institute(GB)Cholangiocarcinoma Foundation(US)

Publications by Year

Research Areas

Pancreatic and Hepatic Oncology Research, Neuroendocrine Tumor Research Advances, Cholangiocarcinoma and Gallbladder Cancer Studies, Lung Cancer Research Studies, Neuroblastoma Research and Treatments

Most-Cited Works

→ Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer(2010)4,329 cited
→ Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors(2011)2,525 cited
→ Pancreatic cancer(2020)2,444 cited
→ Cholangiocarcinoma 2020: the next horizon in mechanisms and management(2020)2,374 cited
→ Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial(2017)1,902 cited
→ Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection(2010)1,380 cited

→ Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study(2015)

1,241 cited

→ Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study(2019)1,194 cited

→ Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study(2020)1,025 cited

→ Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer(2022)1,014 cited